Literature DB >> 25102407

Is there really an increased incidence of thyroid cancer?

Juan P Brito1, Louise Davies.   

Abstract

PURPOSE OF REVIEW: Between 1975 and 2009, the incidence of thyroid cancer has increased from 4.9 to 14.3 cases per 100 000 individuals, with a more pronounced increase in women (from 6.5 to 21.4 cases per 100 000 women). In the USA, in 2013, there are now more cases of thyroid cancer than all leukemias, pancreas and liver cancers combined. This review assesses the current evidence around the hypothesis that thyroid cancer is overdiagnosed: cancers are being detected that were never destined to cause a patient harm. RECENT
FINDINGS: There is a large reservoir of slow or nonprogressing thyroid cancers; up to one-third of the population may unknowingly harbor a thyroid cancer. At least two activities have contributed to the detection of this reservoir of thyroid cancer: the increasing use of advanced imaging modalities in the recent years (i.e., computed tomography and MRI) and increased rates of thyroid surgery coupled with more aggressive evaluation of excised thyroid glands. Despite the increased incidence of thyroid cancer, mortality has not changed over the last 4 decades. This mismatch between incidence and mortality is most consistent with increased identification of nonlethal disease (overdiagnosis).
SUMMARY: Thyroid cancer incidence is increasing, although mortality is stable. The major cause of the increased incidence is detection of subclinical disease - overdiagnosis. Patients are still treated aggressively and are exposed to side-effects of treatment without any certainty of benefit. Strategies to avoid unnecessary intervention and to explicitly involve patients in decision-making should be pursued. Research is needed to help predict which cancers are likely to become problematic.

Entities:  

Mesh:

Year:  2014        PMID: 25102407     DOI: 10.1097/MED.0000000000000094

Source DB:  PubMed          Journal:  Curr Opin Endocrinol Diabetes Obes        ISSN: 1752-296X            Impact factor:   3.243


  29 in total

1.  Polybrominated diphenyl ethers and thyroid cancer risk in the Prostate, Colorectal, Lung, and Ovarian Cancer Screening Trial cohort.

Authors:  Briseis Aschebrook-Kilfoy; Curt T DellaValle; Mark Purdue; Christopher Kim; Yawei Zhang; Andreas Sjodin; Mary H Ward
Journal:  Am J Epidemiol       Date:  2015-05-04       Impact factor: 4.897

Review 2.  The changing incidence of thyroid cancer.

Authors:  Cari M Kitahara; Julie A Sosa
Journal:  Nat Rev Endocrinol       Date:  2016-07-15       Impact factor: 43.330

Review 3.  Total thyroidectomy versus thyroid lobectomy in the treatment of papillary carcinoma.

Authors:  Marco Raffaelli; Serena Elisa Tempera; Luca Sessa; Celestino Pio Lombardi; Carmela De Crea; Rocco Bellantone
Journal:  Gland Surg       Date:  2020-01

Review 4.  A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma.

Authors:  Cristina Romei; Raffaele Ciampi; Rossella Elisei
Journal:  Nat Rev Endocrinol       Date:  2016-02-12       Impact factor: 43.330

5.  Population-Based Assessment of Complications Following Surgery for Thyroid Cancer.

Authors:  Maria Papaleontiou; David T Hughes; Cui Guo; Mousumi Banerjee; Megan R Haymart
Journal:  J Clin Endocrinol Metab       Date:  2017-07-01       Impact factor: 5.958

6.  Evaluation of in vitro and in vivo activity of a multityrosine kinase inhibitor, AL3810, against human thyroid cancer.

Authors:  Qin Xie; Hui Chen; Jing Ai; Ying-Lei Gao; Mei-Yu Geng; Jian Ding; Yi Chen
Journal:  Acta Pharmacol Sin       Date:  2017-08-10       Impact factor: 6.150

7.  Increasing diagnosis of subclinical thyroid cancers leads to spurious improvements in survival rates.

Authors:  Allen S Ho; Louise Davies; Iain J Nixon; Frank L Palmer; Laura Y Wang; Snehal G Patel; Ian Ganly; Richard J Wong; R Michael Tuttle; Luc G T Morris
Journal:  Cancer       Date:  2015-02-24       Impact factor: 6.860

8.  Oncosuppressor-Mutated Cell-Based Diagnostic Platform for Liquid Biopsy Diagnoses Benign Head and Neck Masses and Predicts Malignancy in Thyroid Nodules: Results from a Consecutive Cohort of Patients.

Authors:  Mohamed Abdouh; Roger Tabah; Vincenzo Arena; Manuel Arena; Zu-Hua Gao; Aurelio Lorico; Goffredo Orazio Arena
Journal:  Eur Thyroid J       Date:  2021-06-07

9.  Low trabecular bone score in postmenopausal women with differentiated thyroid carcinoma after long-term TSH suppressive therapy.

Authors:  María Luisa De Mingo Dominguez; Sonsoles Guadalix Iglesias; Cristina Martin-Arriscado Arroba; Begoña López Alvarez; Guillermo Martínez Diaz-Guerra; Jose Ignacio Martinez-Pueyo; Eduardo Ferrero Herrero; Federico Hawkins Carranza
Journal:  Endocrine       Date:  2018-07-16       Impact factor: 3.633

10.  Trends in incidence and histological pattern of thyroid cancer in Ho Chi Minh City, Vietnam (1996-2015): a population-based study.

Authors:  Dung X Pham; Hien D Nguyen; An H T Phung; Tung D Bui; Thach S Tran; Bich N H Tran; Tuan V Nguyen; Lan T Ho-Pham
Journal:  BMC Cancer       Date:  2021-03-20       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.